Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David S Hong

Showing results (291-300 of 442) with videos related to

Pageof 45
Sort By:
JCO Precision Oncology|July 14, 2022
Longitudinal Monitoring of Circulating Tumor DNA to Predict Treatment Outcomes in Advanced CancersMohamed A Gouda, Helen J Huang, Sarina A Piha-Paul, et al.
Cancers|November 7, 2020
Larotrectinib versus Prior Therapies in Tropomyosin Receptor Kinase Fusion Cancer: An Intra-Patient Comparative AnalysisAntoine Italiano, Shivani Nanda, Andrew Briggs, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 19, 2018
Cytokines Produced by Dendritic Cells Administered Intratumorally Correlate with Clinical Outcome in Patients with Diverse CancersVivek Subbiah, Ravi Murthy, David S Hong, et al.
Journal of Medical Internet Research|March 15, 2019
Cancer-Related Internet Use and Its Association With Patient Decision Making and Trust in Physicians Among Patients in an Early Drug Development Clinic: A Questionnaire-Based Cross-Sectional Observational StudyGoldy C George, Eucharia C Iwuanyanwu, Adrianna S Buford, et al.
Current Problems in Cancer|April 18, 2021
Quality of Life in Adult and Pediatric Patients with Tropomyosin Receptor Kinase Fusion Cancer Receiving LarotrectinibShivaani Kummar, Jordan Berlin, Leo Mascarenhas, et al.
Neuro-Oncology|January 27, 2023
Novel murine glioblastoma models that reflect the immunotherapy resistance profile of a human diseaseChao-Hsien Chen, Renee L Chin, Genevieve P Hartley, et al.
The Journal of Clinical Endocrinology and Metabolism|February 4, 2011
Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignanciesDavid S Hong, Maria E Cabanillas, Jennifer Wheler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 13, 2018
Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell CarcinomaDavid S Hong, Kathleen Moore, Manish Patel, et al.
Oncotarget|October 15, 2014
Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trialsRabih Said, Yang Ye, Gerald Steven Falchook, et al.
Cell Reports|January 21, 2014
Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitorsFilip Janku, David S Hong, Siqing Fu, et al.
Pageof 45

Showing results (291-300 of 442) with videos related to

Sort By:
Pageof 45
JCO Precision Oncology|July 14, 2022
Longitudinal Monitoring of Circulating Tumor DNA to Predict Treatment Outcomes in Advanced CancersMohamed A Gouda, Helen J Huang, Sarina A Piha-Paul, et al.
Cancers|November 7, 2020
Larotrectinib versus Prior Therapies in Tropomyosin Receptor Kinase Fusion Cancer: An Intra-Patient Comparative AnalysisAntoine Italiano, Shivani Nanda, Andrew Briggs, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 19, 2018
Cytokines Produced by Dendritic Cells Administered Intratumorally Correlate with Clinical Outcome in Patients with Diverse CancersVivek Subbiah, Ravi Murthy, David S Hong, et al.
Journal of Medical Internet Research|March 15, 2019
Cancer-Related Internet Use and Its Association With Patient Decision Making and Trust in Physicians Among Patients in an Early Drug Development Clinic: A Questionnaire-Based Cross-Sectional Observational StudyGoldy C George, Eucharia C Iwuanyanwu, Adrianna S Buford, et al.
Current Problems in Cancer|April 18, 2021
Quality of Life in Adult and Pediatric Patients with Tropomyosin Receptor Kinase Fusion Cancer Receiving LarotrectinibShivaani Kummar, Jordan Berlin, Leo Mascarenhas, et al.
Neuro-Oncology|January 27, 2023
Novel murine glioblastoma models that reflect the immunotherapy resistance profile of a human diseaseChao-Hsien Chen, Renee L Chin, Genevieve P Hartley, et al.
The Journal of Clinical Endocrinology and Metabolism|February 4, 2011
Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignanciesDavid S Hong, Maria E Cabanillas, Jennifer Wheler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 13, 2018
Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell CarcinomaDavid S Hong, Kathleen Moore, Manish Patel, et al.
Oncotarget|October 15, 2014
Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trialsRabih Said, Yang Ye, Gerald Steven Falchook, et al.
Cell Reports|January 21, 2014
Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitorsFilip Janku, David S Hong, Siqing Fu, et al.
Pageof 45